Summary
BeiGene, Ltd. (ONC) filed an 8-K on November 20, 2020, reporting on the outcome of its 2020 Extraordinary General Meeting (EGM) of Shareholders and a significant regulatory approval in China. The EGM saw strong shareholder participation, with over 88% of outstanding shares represented. The primary resolution approved was the grant of an option to Amgen Inc. to subscribe for up to 75,000,000 ordinary shares, allowing Amgen to maintain approximately 20.6% ownership. This approval is crucial for the ongoing strategic collaboration between BeiGene and Amgen. Furthermore, the company announced that the China National Medical Products Administration (NMPA) has approved XGEVA® (denosumab) for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors and in patients with multiple myeloma. This approval expands the therapeutic applications of XGEVA in China, complementing its existing approval for giant cell tumor of the bone, and is a key milestone for BeiGene's oncology portfolio in a major market.
Key Highlights
- 1Shareholders overwhelmingly approved the grant of an option to Amgen Inc. to subscribe for up to 75,000,000 ordinary shares, enabling Amgen to maintain approximately 20.6% ownership.
- 2The EGM had a high turnout, with approximately 88.61% of outstanding ordinary shares present and voting.
- 3The approval of the Amgen option is tied to a strategic collaboration and supports their ongoing partnership.
- 4The China National Medical Products Administration (NMPA) has approved XGEVA® (denosumab) for the prevention of skeletal-related events (SREs) in China.
- 5This XGEVA approval covers patients with bone metastases from solid tumors and those with multiple myeloma.
- 6XGEVA is already approved and marketed in China for unresectable giant cell tumor of the bone (GCTB).
- 7The NMPA approval signifies an expansion of BeiGene's oncology product offerings in the significant Chinese market.